

Wellnex Life Limited (ASX:WNX)

Wellnex to dual list on the London Stock Exchange

Dual listing of Wellnex on the London Stock Exchange to provide acceleration of our international expansion

Investment highlights

- Wellnex has commenced the process to dual list on the London Stock Exchange that will provide a pathway to accelerate our growth both domestically and internationally.
- Wellnex has appointed UK based Strand Hanson as Financial Advisor for the dual listing on the London Stock Exchange.
- Barclay Pearce Capital and UK based Orana Corporation have been appointed as joint-lead brokers for the dual listing.
- Wellnex listing on the London Stock Exchange will capitalise on our international growth on the back of:
 - Haleon taking our products to the Middle East and European markets.
 - Homart Pharmaceuticals distributing our brands throughout Asia.
- Dual listing provides greater exposure to a larger pool of institutional investors.

Wellnex Life Ltd (ASX:WNX, 'Wellnex', or 'the Company'), an Australian consumer healthcare company working to deliver health, wellness, and vitality solutions to a global marketplace, is pleased to provide an update on the London Stock Exchange listing first announced to the market in a [company update](#) on 5 October 2023.

Since the announcement, Wellnex has conducted extensive due diligence and analysis on the opportunity, including an institutional roadshow, and the Board is pleased to announce that it has appointed UK advisors to dual list the Company's shares on the London Stock Exchange (LSE) in 2024.

Listing on the LSE will provide a platform to continue to grow the company both domestically and internationally and comes at a time where Wellnex will shortly commence taking our brands and products and brands to new international markets.

[As announced on 29 June 2023](#), Wellnex secured an extension of our supply agreement with Haleon to distribute our products into the UK and UAE markets, with supply to commence in FY25.

Furthermore, [as announced on 3 January 2024](#), an exclusive distribution agreement with Homart Pharmaceuticals will take our brands through their extensive distribution network throughout the lucrative Asian markets.

Advisors Appointed

Wellnex has appointed [Strand Hanson](#) as its Financial Advisor to lead the UK advisory team in preparing the required documentation and providing regulatory advice. Wellnex has also appointed [Barclay Pearce Capital](#) and [Orana Corporation](#) as joint-lead brokers for the listing. These appointments follow extensive market analysis by Wellnex, including market-sounding meetings with numerous European small-cap institutional investors.

Reasons for LSE Listing

A dual listing will increase Wellnex's international profile, aligning with the Company's international growth strategy, particularly in Europe where Wellnex has an existing supply agreement with Haleon into the UK and is working on further opportunities both with Haleon and other partners. It will also open the door to a wider pool of institutional investors, with the aim of generating additional global investor interest that will drive exposure for the business and increase shareholder value.

Mario Tascone, Chairman of Wellnex, commented: "I am delighted to announce we are officially starting the LSE listing process and am excited by the opportunity it presents Wellnex. While we continue to concentrate and increase our presence in the domestic market, this will open up opportunities to grow the business by taking advantage of the numerous opportunities internationally."

–Ends–

Authorised for release by the Board, for further information please contact:

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/